TLSA Strangle Strategy
TLSA (Tiziana Life Sciences Ltd), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.
TLSA (Tiziana Life Sciences Ltd) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $89.1M, a beta of 0.42 versus the broader market, a 52-week range of 1.14-2.6, average daily share volume of 144K, a public-listing history dating back to 2018, approximately 9 full-time employees. These structural characteristics shape how TLSA stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.42 indicates TLSA has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a strangle on TLSA?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current TLSA snapshot
As of May 15, 2026, spot at $1.40, ATM IV 22.40%, IV rank 1.11%, expected move 6.42%. The strangle on TLSA below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on TLSA specifically: TLSA IV at 22.40% is on the cheap side of its 1-year range, which favors premium-buying structures like a TLSA strangle, with a market-implied 1-standard-deviation move of approximately 6.42% (roughly $0.09 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated TLSA expiries trade a higher absolute premium for lower per-day decay. Position sizing on TLSA should anchor to the underlying notional of $1.40 per share and to the trader's directional view on TLSA stock.
TLSA strangle setup
The TLSA strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With TLSA near $1.40, the first option leg uses a $1.47 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed TLSA chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 TLSA shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $1.47 | N/A |
| Buy 1 | Put | $1.33 | N/A |
TLSA strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
TLSA strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on TLSA. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on TLSA
Strangles on TLSA are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the TLSA chain.
TLSA thesis for this strangle
The market-implied 1-standard-deviation range for TLSA extends from approximately $1.31 on the downside to $1.49 on the upside. A TLSA long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current TLSA IV rank near 1.11% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on TLSA at 22.40%. As a Healthcare name, TLSA options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to TLSA-specific events.
TLSA strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. TLSA positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move TLSA alongside the broader basket even when TLSA-specific fundamentals are unchanged. Always rebuild the position from current TLSA chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on TLSA?
- A strangle on TLSA is the strangle strategy applied to TLSA (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With TLSA stock trading near $1.40, the strikes shown on this page are snapped to the nearest listed TLSA chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are TLSA strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the TLSA strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 22.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a TLSA strangle?
- The breakeven for the TLSA strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current TLSA market-implied 1-standard-deviation expected move is approximately 6.42%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on TLSA?
- Strangles on TLSA are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the TLSA chain.
- How does current TLSA implied volatility affect this strangle?
- TLSA ATM IV is at 22.40% with IV rank near 1.11%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.